

OMB APPROVAL	
OMB Number:	3235-0415
Expires:	February 28, 2009
Estimated average burden hours per response	10.4

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## SCHEDULE 13G

(Rule 13d-102)

Information to Be Included in Statements Filed Pursuant to Rules 13d-1 (b), (c), and (d)  
and Amendments Thereto Filed Pursuant to Rule 13d-2

(Amendment No. \_\_\_\_\_)\*

---

**Sucampo Pharmaceuticals, Inc.**

(Name of Issuer)

---

**Class A Common Stock**

(Title of Class of Securities)

---

**864909106**

(CUSIP Number)

---

**December 31, 2007**

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

---

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

1	NAME OF REPORTING PERSONS ORIX Corporation		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* Not Applicable		
3	SEC USE ONLY		
4	CITIZENSHIP OR PLACE OF ORGANIZATION Tokyo, Japan		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 1,981,712	(a) 0 (b) 0
	6	SHARED VOTING POWER 0	
	7	SOLE DISPOSITIVE POWER 1,981,712	
	8	SHARED DISPOSITIVE POWER 0	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,981,712		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 0		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 12.6%		
12	TYPE OF REPORTING PERSON CO		

**Item 1(a). Name of Issuer:**

Sucampo Pharmaceuticals, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**

4520 East-West Highway, Suite 300, Bethesda, MD 20814

**Item 2(a). Name of Person Filing:**

ORIX Corporation

**Item 2(b). Address of Principal Business Office or, if None, Residence:**

Mita NN Building, 4-1-23, Shiba, Minato-ku, Tokyo, Japan 108-0014

**Item 2(c). Citizenship:**

Tokyo, Japan

**Item 2(d). Title of Class of Securities:**

Class A Common Stock

**Item 2(e). CUSIP Number:**

864909106

**Item 3. If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:**

- (a)  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Not applicable.

**Item 4. Ownership.**

Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

- (a) Amount beneficially owned: 1,981,712
- (b) Percent of class: 12.6%
- (c) Number of shares as to which such person has:
  - (i) Sole power to vote or to direct the vote: 1,981,712
  - (ii) Shared power to vote or to direct the vote: 0
  - (iii) Sole power to dispose or to direct the disposition of: 1,981,712
  - (iv) Shared power to dispose or to direct the disposition of: 0

**Item 5. Ownership of Five Percent or Less of a Class.**

Not Applicable

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable. The Reporting Persons expressly disclaim membership in a "group" as used in Rule 13d-1(b)(ii)(J).

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certifications.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

June 15, 2012

\_\_\_\_\_  
Date

/s/ Haruyuki Urata

\_\_\_\_\_  
Signature

Haruyuki Urata / Director, Deputy President, ORIX  
Corporation

\_\_\_\_\_  
Name/Title